{"id":62516,"date":"2026-01-20T16:06:04","date_gmt":"2026-01-20T15:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/"},"modified":"2026-01-20T16:06:04","modified_gmt":"2026-01-20T15:06:04","slug":"neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/","title":{"rendered":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis"},"content":{"rendered":"
\n

\nASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition<\/i><\/p>\n

IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness<\/a>—NeuroQure<\/a>, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD Insight provides clinicians and families with unprecedented early insight into autism risk, enabling earlier, targeted interventions during the most critical stages of neurodevelopment.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cAutism is treatable, and research<\/a> has demonstrated that early intervention significantly enhances cognitive, social, and behavioral development. However, the average age of autism diagnosis in the United States remains at five years, long after critical developmental windows have passed,\u201d said Dr. John \u201cJay\u201d Gargus, MD, PhD, Founding Scientist & Chief Scientific Officer at NeuroQure and Professor Emeritus of Physiology & Biophysics and Pediatric Medical Genetics & Genomics at the University of California, Irvine, where he also served as Founding Director of the Center for Autism Research and Translation.<\/p>\n

\nIt is Dr. Gargus\u2019s pioneering work on calcium signaling and mitochondrial dysfunction in autism that laid the foundation for the ASD Insight test. Utilizing an advanced optical patch clamp technique, the test identifies mitochondrial and neurotransmitter dysfunctions associated with autism. NeuroQure\u2019s CLIA-certified lab processes skin biopsy samples, providing clinicians with risk assessments within weeks.<\/p>\n

\n\u201cFor years, our research has demonstrated that dysregulated calcium signaling is a unifying final common pathway leading to pathophysiological features across diverse autism genotypes,\u201d said Dr. Gargus. \u201cASD Insight represents the first clinical application of this knowledge, enabling the detection of biophysical and metabolic dysfunctions at a cellular level before behavioral symptoms emerge, as early as at birth. It\u2019s a critical step toward redefining autism as a biologically measurable condition rather than one diagnosed solely through observation.\u201d<\/p>\n

\nStudies show that children who begin autism treatment by age two experience significant cognitive and social improvements, with many achieving independent living and workforce participation, and new approaches are demonstrating that effective therapy can begin by six months. In contrast, delayed diagnosis and intervention can lead to increased dependency and higher lifetime medical costs.<\/p>\n

\n\u201cSimply put, early diagnosis means early treatment, and early treatment leads to brighter futures,\u201d said David Justus, Founder & CEO of NeuroQure. \u201cWith this test, we can provide families with the knowledge they and their physicians need to make informed decisions about their child\u2019s development from the very start, significantly impacting the trajectory of their lives.\u201d<\/p>\n

\nThe test is now available at https:\/\/www.neuroqure.com\/order<\/a>.<\/p>\n

\nAbout NeuroQure<\/b><\/p>\n

\nNeuroQure develops molecular assays for neurological conditions, with an emphasis on early detection and risk assessment. The company applies scientific research to support healthcare providers in identifying neurodevelopmental disorders. For more information, visit https:\/\/www.neuroqure.com\/<\/b><\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMelissa Skabich
\n
PCE Communications
\n
mskabich@pcecommunications.com<\/a>
973-760-9926<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness—NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62516","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness—NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T15:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis\",\"datePublished\":\"2026-01-20T15:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/\"},\"wordCount\":489,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120058832\\\/en\\\/2695826\\\/22\\\/NQ_Logo_-_high_res.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/\",\"name\":\"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120058832\\\/en\\\/2695826\\\/22\\\/NQ_Logo_-_high_res.jpg\",\"datePublished\":\"2026-01-20T15:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120058832\\\/en\\\/2695826\\\/22\\\/NQ_Logo_-_high_res.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120058832\\\/en\\\/2695826\\\/22\\\/NQ_Logo_-_high_res.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/","og_locale":"en_US","og_type":"article","og_title":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend","og_description":"ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness—NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-20T15:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis","datePublished":"2026-01-20T15:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/"},"wordCount":489,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/","url":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/","name":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg","datePublished":"2026-01-20T15:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260120058832\/en\/2695826\/22\/NQ_Logo_-_high_res.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neuroqure-launches-first-ever-functional-biophysical-marker-test-for-autism-transforming-early-autism-risk-diagnosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NeuroQure Launches First-Ever Functional Biophysical Marker Test for Autism, Transforming Early Autism Risk Diagnosis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62516"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62516\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}